相关实验视频

Updated: Jul 5, 2025

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

在帕金森病的转基因A53Tα-synuclein模型中,利沃多巴拯救了视网膜功能

Katie K N Tran¹, Vickie H Y Wong¹, Kirstan A Vessey²

¹Department of Optometry and Vision Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.

|January 23, 2024

概括

莱沃多巴 (L-DOPA) 治疗改善了帕金森病 (PD) 鼠标模型中的视觉功能,该模型具有α-synuclein过度表达. 然而,L-DOPA并没有逆转视网膜稀释,突出显示了PD中复杂的多巴胺-α-同核素相互作用.

科学领域:

神经科学是一个神经科学.
眼科医生眼科眼科
药理学药理学是指药理学的学科.

背景情况:

帕金森病 (PD) 的特点是多巴胺基细胞损失和α-syn核素 (α-syn) 沉积.
利沃多巴 (L-DOPA) 是PD症状的主要治疗方法.
在PD模型中的视网膜变化和L-DOPA的影响尚未完全理解.

研究的目的:

在转基因PD小鼠模型中研究视网膜结构和功能变化.
在此PD模型中评估急性勒沃多巴 (L-DOPA) 治疗对视网膜功能和结构的影响.

主要方法:

使用过度表达A53Tα-synuclein (HOM) 和野生型 (WT) 的小鼠.
用L-DOPA或载体进行腹膜内注射.
通过电网膜学 (ERG) 评估视网膜功能,通过光学相干断层学 (OCT) 评估视网膜结构.
使用免疫组织化学 (IHC) 的量化氨酸氧酶 (TH) 阳性细胞.

主要成果:

与WT小鼠相比,L-DOPA在A53T HOM小鼠中显著提高了ERGa波和b波的幅度.
在A53T HOM小鼠中观察到外视网膜稀释 (ONL,OPL).
L-DOPA没有改善观察到的视网膜稀释.
没有注意到TH阳性亚马克林细胞的显著变化.

结论:

急性L-DOPA治疗提供了与α-synuclein积累相关的视觉功能障碍的暂时改善.
这些发现提高了对视网膜中多巴胺-α-synuclein相互作用的理解.
建立了一个临床前框架,用于查PD治疗方法.

关键词:

在A53T小鼠中.帕金森病是帕金森氏症的一种疾病.亚马克林细胞是一种细胞.电网红学 (electroretinography) 是一种电网红学 (electroretinography) 的方法,可以通过电网红学 (electroretinography) 进行测试.免疫组织化学免疫组织化学利沃多帕 (levodopa) 是一种可以使用的药物.光学连贯性断层扫描 (optical coherence tomography) 是一种光学连贯性断层扫描技术.

更多相关视频

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.